Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- DPT-IPV Vaccine Quattrovac to Be Out of Stock in November
October 29, 2015
- Yakult Licenses Novel Platelet Increasing Agent from Nissan Chemical
October 28, 2015
- Lupin Names Fabrice Egros As President of Asia Pacific, Japan Operations
October 28, 2015
- Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
- Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
October 26, 2015
- Lilly Joins NCC’s SCRUM-Japan Genomic Screening Project
October 26, 2015
- GSK to Transfer 3 Oncology Products to Novartis in Japan in November
October 26, 2015
- Sandoz Looking to Emerge as Top Foreign Generic Maker in Japan in 5 Years
October 23, 2015
- Chugai to Build New Antibody API Manufacturing Plant
October 23, 2015
- Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
October 23, 2015
- Belsomra Most Promoted Drug for 2 Months on End: Anterio Ranking
October 21, 2015
- Development of Osteoporosis Drugs in Homestretch, Odanacatib’s US Filing Expected by Year-End
October 21, 2015
- Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
- Kowa Seeks Japan Approval of Livalo Successor Pemafibrate
October 20, 2015
- Daiichi Sankyo to Shed 1,000 Jobs in US
October 20, 2015
- Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
- Eisai, Ajinomoto Link Arms to Create Leading Specialty Pharma for GI Disease
October 16, 2015
- MSD Files Allergy Drug Desloratadine in Japan
October 16, 2015
- Eisai’s GI Disease Biz to Integrate with Ajinomoto Pharma
October 15, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…